Streetbeat News

Earnings

ESEA

Euroseas Ltd. (NASDAQ:ESEA) announced a one-year time charter contract for its containership, M/V Synergy Antwerp, at a daily rate of $26,500, starting April 2, 2024. The ship underwent retrofits, including energy-saving devices, expected to reduce CO2 emissions by 9,800 metric tons annually. These upgrades are part of Euroseas' efforts to modernize its fleet and reduce its carbon footprint. The charter is expected to contribute about $6.5 million of EBITDA and increases Euroseas' 2024 charter coverage to 80%.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 1:03 pm

EL

Estee Lauder Cos (NYSE:EL) has been evaluated by 12 analysts over the last three months, showing a diverse range of opinions. Recent updates include raised price targets and ratings, with an average 12-month price target of $160.17, marking a 17.0% increase from the previous average of $136.90. The company is a leader in the global prestige beauty market but faces challenges with a -7.38% revenue growth decline over 3 months. Despite this, it maintains strong profitability metrics.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 1:00 pm

VEEV

20 analysts have recently reviewed Veeva Systems (NYSE:VEEV), showing a mix of bullish and bearish sentiments. The average 12-month price target is now $243.5, up from $219.00, indicating an 11.19% increase. Analysts' ratings range from 'Buy' to 'Underweight', with several maintaining their previous ratings and others raising their price targets. Veeva Systems, a leading provider of cloud-based solutions for the life sciences industry, has shown strong financial performance with a revenue growth rate of 11.93%, a net margin of 23.37%, and an ROE of 3.27%.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 1:00 pm

MVST

Microvast targets a Q1 2024 revenue growth of 40%-60% YoY, with guidance of $65M-$75M, below the $132.84M estimate. The company aims for a gross margin of 20%-25%, plans to complete Clarksville Phase 1A with financing solutions, and secure long-term domestic customer contracts. It also reports new customer wins in APAC and EMEA, expanding its presence in the electrifying commercial vehicle markets.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 1:00 pm

COCO

CSCO

KGS

PLTR

TYL

UAL

Jim Cramer recommended buying Tyler Technologies (TYL) and holding Cisco Systems (CSCO). He suggested selling Kodiak Gas Services (KGS) due to its recent price increase and poor earnings report. Cramer praised Vita Coco (COCO) for its positive financial results and recommended 'ka-ching'-ing United Airlines (UAL) due to potential operational challenges. He also liked Palantir Technologies (PLTR) for its defense business, despite a downgrade by an analyst.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 12:58 pm

ONFO

Onfolio Holdings reported a Q4 2023 revenue of $1.27M, marking an increase from $1.12M in the same quarter the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:55 pm

EAST

Eastside Distilling's shares have declined due to the company reporting Q4 results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:53 pm

MVST

Microvast Holdings' shares are trading lower despite the company reporting better than expected earnings for the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:53 pm

MU

OUST

SGH

As of April 2, 2024, SMART Global Holdings, Inc. (SGH), Micron Technology, Inc. (MU), and Ouster, Inc. (OUST) are identified as overbought tech stocks with RSI values above 70, indicating potential short-term performance concerns. SGH announced a $75 million share repurchase and gained 14% over the past month. MU received a Buy rating from B of A Securities with a raised price target, gaining 30% over the past month. OUST reported record revenue and bookings for 2023, gaining 99% over the past five days.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 12:46 pm

VCNX

Vaccinex announced it expects topline data from its Phase 1/2a randomized SIGNAL-AD study of Pepinemab for Alzheimer's Disease in Q3 2024. This marks a significant milestone in the development of treatments for Alzheimer's, potentially impacting the company's stock as investors anticipate the results.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:45 pm